SCHEMBL856826

SCHEMBL856826

Cc1ncnc(N2CCOc3ccc(-c4ccc5nc(N)[nH]c5n4)cc3C2)c1Cc1ccc(F)cc1

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KIT P10721 9/20 0.35
GRIA1 P42261 1/20 0.34
LRRK2 Q5S007 2/20 0.33
STK4 Q13043 1/20 0.33
STK3 Q13188 1/20 0.33
RPS6KB1 P23443 2/20 0.32
IGF1R P08069 1/20 0.32
GPR142 Q7Z601 1/20 0.31
PIK3CA P42336 2/20 0.31
ROCK2 O75116 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857055 0.89 GRIA1 (0.43) KITGRIA1RPS6KB1IGF1RPIK3CA
SCHEMBL858284 0.88 GRIA1 (0.37) KITGRIA1LRRK2STK4STK3
SCHEMBL858622 0.85 PIK3CA (0.35) KITRPS6KB1PIK3CAROCK2
SCHEMBL856838 0.84 SLC6A2 (0.36) KITLRRK2STK4STK3RPS6KB1
SCHEMBL861032 0.83 PIK3CA (0.47) KITGRIA1IGF1RGPR142PIK3CA
SCHEMBL856296 0.83 GRIA1 (0.34) KITGRIA1RPS6KB1IGF1RGPR142
SCHEMBL856498 0.83 RPS6KB1 (0.32) KITRPS6KB1
SCHEMBL858299 0.83 RPS6KB1 (0.36) KITLRRK2STK4STK3RPS6KB1
SCHEMBL858938 0.82 KIT (0.36) KITRPS6KB1GPR142PIK3CA
SCHEMBL3722126 0.82 LRRK2 (0.35) KITLRRK2STK4STK3RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US claimed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KIT 224/4885GRIA1 528/4885LRRK2 1459/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KIT 190/4885GRIA1 539/4885LRRK2 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.